Heterogeneous ribonucleoproteins (hnRNP) are a large family of ribonucleic acid (RNA) binding proteins that contribute to functions involved in transcription and translation regulation 6 . hnRNPs are primarily a nuclear protein but translocate to the cytoplasm in response to cellular stress such as hypoxia, UV-radiation, or cold stress. Elevated levels of hnRNP A18 have been detected in the cytoplasm of tumor cells in different cancers such as melanoma, acute myeloid leukemia, and Ewing Sarcoma. Inhibition of hnRNP A18 has resulted in reduced tumor weight and tumor suppression making hnRNP A18 an ideal target for small molecule inhibition. Through collaborative efforts with Dr. Alexander MacKerell, Jr., and the Computer Aided Drug Design (CADD) group while using SILCS technology, researchers have been able to develop molecular scaffolds with the ability to inhibit hnRNP A18 binding activity. We hypothesize that by using these molecular scaffolds, novel hnRNP A18 inhibitors can be synthesized to inhibit hnRNP A18- RNA binding preventing tumor formation and development.